fool.comNov 6$AMPH

Amphastar (AMPH) Q3 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q3 2026 revenue of $207.6M, up 8% YoY, driven by BAQSIMI and Primatene MIST sales. Gross margin fell to 48% due to pricing pressures and IMS facility remediation costs. EPS rose to $1.14. The company increased its share buyback program by $50M and expects high single-digit Q4 growth. IMS backlog stands at $12.5M due to operational constraints. Insulin aspart launch is targeted for 2027, pending FDA approval.

Original reporting

fool.com

Published Nov 6, 2026, 4:08 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 4:31 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Amphastar (AMPH) Q3 2026 Earnings Call Transcript — source image — Source · fool.com

Decision brief

The 30-second read

$AMPHBullishHigh

Why it matters

The earnings beat and buyback expansion are likely to generate buying interest, while margin pressure and remediation costs introduce downside risk.

Market read

First‑report earnings with better‑than‑expected revenue and EPS, plus a $50M buyback increase, provide a fresh catalyst for AMPH, making the article highly relevant for traders.

What to watch

Potential regulatory scrutiny on 340B discounting and upcoming biosimilar approvals may affect future earnings.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Amphastar Pharmaceuticals reported its Q3 2026 earnings, highlighting revenue growth, product performance, and a larger buyback program amid remediation at its IMS facility.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMPHBullishHigh confidence

Context

Q3 2026 earnings released with $207.6M revenue, 8% YoY growth, adjusted EPS $1.14 and $50M buyback increase.

Expected impact

potential modest upside as market prices in revenue beat and buyback expansion, tempered by margin pressure.

Evidence & confidence

First‑report earnings with better‑than‑expected revenue and EPS, plus a $50M buyback increase, typically drive buying pressure; however, gross margin fell to 48% and remediation costs rise, which may cap gains.

Market effects

Sector

Positive signal for specialty pharma and biotech peers focusing on biosimilars and inhaled therapies.

Regional

Limited to US specialty pharma sector; no broader regional effect.

Global

Minimal global impact beyond niche therapeutic markets.

Counterpoint

What could challenge this read

Margin compression and ongoing IMS remediation could outweigh short‑term upside, leading to a pullback.

Key entities

Company
Amphastar Pharmaceuticals, Inc.
US‑listed specialty pharma company (ticker AMPH) reporting Q3 2026 results.

Read at source ← All news

$AMPHHighAI 8/10

Amphastar Pharmaceuticals Inc (AMPH) Q3 2026 Earnings Call Highlights: Record Revenue

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.

finance.yahoo.comNov 6

$AMPHMed

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

finance.yahoo.comNov 6

$AMPHHighAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars

Amphastar Pharmaceuticals (AMPH) reported Q3 2026 revenue of $207.6M, up 8.2% YoY and 5.9% above estimates. Adjusted EPS of $1.14 beat estimates by 32.8%. Operating margin was 24.5%, in line with the prior year. The company cited strong sales of key products and pipeline advancements. Shares rose 7.2% post-results.

finance.yahoo.comNov 5

$AMPHMed

Amphastar Pharmaceuticals 3Q 2026: Revenue $207.61M, EPS $0.87 — 10-Q Summary

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61M, up 8.2% YoY, and net income of $37.76M, up 117.7% YoY. Growth in BAQSIMI, Primatene MIST, and lidocaine sales offset declines in epinephrine and glucagon. New ipratropium bromide sales contributed $6.6M. Lower expenses also boosted income.

tradingview.comNov 5

$AMPHHigh

Amphastar Reports Q3 Revenue of $207.6 Million and Adjusted EPS of $1.14

Amphastar reported Q3 2026 revenue of $207.6M, up 8% YoY, with GAAP net income of $37.8M. Adjusted EPS was $1.14. Key products like BAQSIMI and Primatene MIST saw sales growth, while Lidocaine and Ipratropium bromide performed strongly. Teriparatide and API sales also contributed to growth. Manufacturing issues impacted some product sales and expenses.